These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. Piscaglia F, Donati G, Gaiani S, Gramantieri L, Leoni S, Mancini M, Bolondi L. Dig Liver Dis; 2004 Sep; 36(9):594-602. PubMed ID: 15460844 [Abstract] [Full Text] [Related]
6. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. Escorsell A, Feu F, Bordas JM, García-Pagán JC, Luca A, Bosch J, Rodés J. J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728 [Abstract] [Full Text] [Related]
7. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Morillas RM, Planas R, Cabré E, Galán A, Quer JC, Feu F, García Pagán JC, Bosch J, Gassull MA. Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651 [Abstract] [Full Text] [Related]
8. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, Soriano G, Guarner C, Balanzó J. J Hepatol; 2004 May; 40(5):757-65. PubMed ID: 15094222 [Abstract] [Full Text] [Related]
10. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Garcia-Pagán JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Hepatology; 1990 Feb; 11(2):230-8. PubMed ID: 2307401 [Abstract] [Full Text] [Related]
12. The effect of a combined treatment with propranolol and isosorbide-5-mononitrate on Doppler ultrasound parameters in patients with cirrhosis and portal hypertension. Orban Schiopu AM, Balas BI, Diculescu M. Rom J Gastroenterol; 2005 Jun; 14(2):123-7. PubMed ID: 15990930 [Abstract] [Full Text] [Related]
13. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Navasa M, Chesta J, Bosch J, Rodés J. Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055 [Abstract] [Full Text] [Related]
19. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, Gatta A. Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449 [Abstract] [Full Text] [Related]
20. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. García-Pagán JC, Feu F, Navasa M, Bru C, Ruiz del Arbol L, Bosch J, Rodés J. J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914 [Abstract] [Full Text] [Related] Page: [Next] [New Search]